European Journal of Internal Medicine
Volume 20, Issue 5 , Pages 490-493 , September 2009

Decline of viral hepatitis prevalence among asymptomatic Egyptian blood donors: A glimmer of hope

Received 18 November 2007 ,Revised 30 December 2008 ,Accepted 4 March 2009.

References 

  1. Cohen J. The scientific challenge of hepatitis C. Science. 1999;285(5424):26–30
  2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41–52
  3. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75:347–354
  4. Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology. 2006;43(5):915–922
  5. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–891
  6. Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 2000;32(1):111–115
  7. Nafeh MA, Medhat A, Shehata M, Mikhail NN, Swifee Y, Abdel-Hamid M, et al. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. Am J Trop Med Hyg. 2000;63(5–6):236–241
  8. Arthur RR, Hassan NF, Abdallah MY, el-Sharkawy MS, Saad MD, Hackbart BG, et al. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Trans R Soc Trop Med Hyg. 1997;91:271–274
  9. Abdul Mujeeb S, Nanan D, Sabir S, Altaf A, Kadir M. Hepatitis B and C infection in first-time blood donors in Karachi—a possible subgroup for sentinel surveillance. East Mediterr Health J. 2006;12(6):735–741
  10. Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol. 2006;44(3):455–461
  11. Palitzsch KD, Hottentrager B, Schlottmann K, et al. Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol. 1999;11:1215–1220
  12. Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol. 2000;14:575–580
  13. Desenclos JC. Epidemiology of hepatitis C. Revue du Praticien. 2000;50:1066–1070
  14. Law MG, Dore GJ, Bath N, et al. Modelling hepatitis C virus incidence, prevalence, and long-term sequelae in Australia, 2001. Int J Epidemiol. 2003;32:717–724
  15. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562
  16. Puro V, Petrosillo N, Ippolito G, Aloisi MS, Boumis E, Rava L. Occupational hepatitis C virus infection in Italian health care workers. Am J Public Health. 1995;85:1272–1275
  17. Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol. Jul 2005;76(3):327–332
  18. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer. Apr 10 2007;96(7):1127–1134
  19. Tanaka J, Mizui M, Nagakami H, Katayama K, Tabuchi A, Komiya Y, et al. Incidence rates of hepatitis B and C virus infections among blood donors in Hiroshima, Japan, during 10 years from 1994 to 2004. Intervirology. Feb 29 2008;51(1):33–41
  20. Mohamed MK. Epidemiology of HCV in Egypt 2004. Afro-Arab Liver J. 2004;3(2):41–52
  21. Mohamed MK, Hussein MH, Massoud AA, Rakhaa MM, Shoeir S, Aoun AA, et al. Study of the risk factors for viral hepatitis C infection among Egyptians applying for work abroad. J Egypt Public Health Assoc. 1996;71(1–2):113–147
  22. Farghaly AG, Mansour GA, Mahdy NH, Yousri A. Hepatitis B and C virus infections among patients with gingivitis and adult periodontitis: seroprevalence and public health importance. J Egypt Public Health Assoc. 1998;73(5–6):707–735
  23. Shepard Colin W, Finelli Lyn, Alter Miriam J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567
  24. Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD. Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol. 2002;40(5):1656–1659
  25. Hutin Y, Hauri A, Chiarello L, et al. Best infection control practices for intradermal, subcutaneous, and intramuscular injections. Bull World Health Organ. 2003;81:491–500
  26. Bhavesh B, Shah MD, Wong John B. The economics of hepatitis C virus. Clin Liver Dis. 2006;10:717–734
  27. Talaat M, Kandeel A, Rasslan O, Hajjeh R, Hallaj Z, El-Sayed N, et al. Evolution of infection control in Egypt: achievements and challenges. Am J Infect Control. 2006;34(4):193–200

PII: S0953-6205(09)00042-9

doi: 10.1016/j.ejim.2009.03.005

European Journal of Internal Medicine
Volume 20, Issue 5 , Pages 490-493 , September 2009

Article Tools

* Image Usage & Resolution